The effect of Montelukast and Gabapentin on pruritus in hemodialysis patients

Comparison of the effect of Montelukast with gabapentin in reducing uremic pruritus in hemodialysis patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180617040114N3

Enrollment

Registered

2020-12-02

Start date

2020-06-29

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dialysis patients. Unspecified complication of foreign body accidentally left in body following kidney dialysis

Interventions

Intervention 1: Intervention group: This group is given Montelukast capsules. At the beginning of the study, a dose of 100 mg will be given to individuals, and after follow-up, if there are no side ef

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with chronic renal failure Equal number of dialysis sessions per week Do not take itching drugs Perform hemodialysis for at least 6 months

Exclusion criteria

Exclusion criteria: Having skin diseases Patients whose hemodialysis has been stopped for any reason or is on the kidney transplant list Lack of uremic pruritus

Design outcomes

Primary

Measure	Time frame
Pruritus rate. Timepoint: It is measured one day before the intervention and 8 weeks after the intervention. Method of measurement: Using Visual analogue scale questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmirreza laripourtehranfar

Arak University of Medical Sciences

amirreza_als@yahoo.com+98 86 3417 3645

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026